Eurofins Scientific announces that it has signed an exclusive agreement to acquire PHAST Gesellschaft für Pharmazeutische Qualitätsstandards mbH (“PHAST”), one of Europe’s leading service providers in the field of pharmaceutical products quality. The transaction is expected to close in the ... more
Eurofins expands in IndiaAcquires biopharmaceutical company Advinus from Tata Group
Eurofins Scientific announces that it has signed an exclusive agreement with Tata Group to acquire Advinus Therapeutics, a preclinical and clinical phase contract research company for Safety Assessment, DMPK, CMC services, and Analytical R&D Services. The transaction is expected to close in the next few weeks, subject to the fulfilment of customary closing conditions.
With over 25 years of GLP compliance and certification, Advinus serves diverse industries such as Biotech, Pharmaceuticals, Biologics, Agrochemicals, Nutraceuticals and Cosmetics. Advinus has submitted over 50 end-to-end investigational new drug applications (INDs) to global regulators such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency in the UK (MHRA) and Health Canada among others. Located in Bangalore, India, the company operates a state-of-the art 20,000 m2 facility on a large campus with ample space for expansion. The company generated revenues of EUR 17m in the Fiscal Year ending 31 March 2017 with over 300 staff.
Advinus’ expertise complements Eurofins recent contract research, development and manufacturing (CDMO) capabilities following the acquisitions of Alphora in Canada and Amatsigroup in Europe. The company provides GMP testing and manufacturing capabilities, and is well positioned to capitalize on the growing R&D outsourcing market in the Asia-Pacific region.
Comment from Mr. KRS Jamwal, Chairman of Advinus and Executive Director of Tata Industries: “Advinus has developed significant promise under Tata parenting, and will now realise its full potential joining the Eurofins family of laboratories. We are confident that with access to Eurofins’ global network and technical competencies, Advinus will be able to rapidly expand its analytical portfolio and services to benefit all its existing and future clients.”
Comment from Dr. Gilles Martin, Eurofins CEO: “We are pleased to welcome Advinus Therapeutics to the Eurofins Group. Advinus’ competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market. We are committed to supporting Advinus’ further development by providing access to the full range of services and capabilities of the Group to the company and its clients.”
- contract research o…
- contract development
- contract research
- contract manufacturing
- pharmaceutical cont…
- Tata Group
Eurofins Scientific announces that it has successfully closed the transaction to acquire Protec Group’s water and food testing businesses in France (“Protec Bio-testing”). This acquisition comprises two laboratories with a total surface area over 1,500 m2. One laboratory is mainly focused o ... more
Eurofins Scientific (EUFI.PA) announces that it has successfully closed the transaction to acquire Lab Frontier Co., Ltd., which provides a broad suite of food, environment and cosmetics testing services in South Korea. Lab Frontier, an affiliate company of Young In Group (YIG), will furthe ... more
- Genetic screening before embryo transfer fails to improve the chance of a baby
- Eurofins acquires German pharma quality service company
- Direct optical reading of single-molecule DNA bases in modified nanopores
- Cancer: Tumor transition states
- Eurofins aquires food and water testing activities business of Protec Group